Drug news
FDA grants extended approval for Trisenox to treat acute promyelocytic leukemia
Teva Pharmaceutical Industries Ltd. announced that the FDA has approved the use of Trisenox (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.